

**Certificate of Mailing by Express Mail**

Express Mail Label No.: EV 399287591 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

By: Barbara Bryant Date: April 15, 2004  
Barbara Bryant

PATENT  
Attorney Docket No. P-022-US5  
Customer Number 27038

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
Martin S. LINSELL	)	Group Art Unit: Not yet assigned
	)	
Application No.: Not yet assigned	)	Examiner: Not yet assigned
(Continuation of U.S. 10/092,088)	)	
	)	
Filed: On Even Date Herewith	)	
	)	
For: INTERMEDIATE FOR PREPARING	)	
GLYCOPEPTIDE DERIVATIVES	)	

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 CFR §1.56, Applicants hereby submit the following information in conformance with CFR §§1.97 and 1.98.

Enclosed herewith is a form PTO/SB/08a which lists documents for consideration by the Examiner. Copies of the cited documents are also enclosed herewith.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Consideration of the listed documents is respectfully requested. Additionally, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO/SB/08a to Applicant with the next communication in this application.

Pursuant to 37 C.F.R. §1.98(a)(3)(i), a concise explanation of the relevance of the following non-English language document is provided:

- (1) WO 92/17456 A1 (in Japanese) is believed to disclose methyl(2-oxo-ethyl)carbamic acid 9-fluorenylmethyl ester. An English-language abstract is also enclosed for this document.

Applicant also wishes to bring to the Examiner's attention the following related, commonly-owned applications:

- (1) U. S. Serial No. 09/470,209, filed December 22, 1999 (now U. S. Patent No. 6,392,012);
- (2) U. S. Serial No. 09/656,473, filed September 6, 2000 (now U. S. Patent No. 6,444,786);
- (3) U. S. Serial No. 09/674,456, filed November 1, 2000 (now U. S. Patent No. 6,455,669); and
- (4) U. S. Serial No. 10/092,088, filed March 6, 2002.

This Information Disclosure Statement is being filed on even date with the above-identified patent application. Accordingly, no fee or certification is required under 37 CFR §1.97(b). However, in the event that a fee is required, the Commissioner is hereby authorized to charge any such fees to Deposit Account No. 50-0344.

Should there be any questions concerning the cited document, the Examiner is encouraged to telephone the undersigned agent for Applicants at (650) 808-6144.

Respectfully submitted,

THERAVANCE, INC.

Date: April 15, 2004

By: Joyce G. Cohen  
Joyce G. Cohen  
Registration No. 44,622

THERAVANCE, INC.  
901 Gateway Boulevard  
South San Francisco, CA 94080  
Tel: (650) 808-6000  
Fax: (650) 808-6078

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	Not yet assigned
Filing Date	On Even Date Herewith
First Named Inventor	Martin S. LINSELL
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	P-022-US5

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B1	WO 92/17456 A1(in Japanese with English abstract)	10-15-1992	Fujisawa Pharmaceutical Co., Ltd.		
	B2	WO 99/42476 A1	08-26-1999	Advanced Medicine, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.